Matthew J. Friedman, MD
Professor of Psychiatry
Professor of Pharmacology & Toxicology
Pharmacology & Toxicology
Dartmouth College, AB 1961
Einstein College of Medicine, PHD 1967
U. Kentucky, MD 1969
Neuroscience Center at Dartmouth
Dartmouth Medical School
Hanover NH 03755
Dr. Matthew J. Friedman received his Ph.D. in pharmacology at the Albert Einstein College of Medicine in 1967. He then received an M.D. at the University of Kentucky, Lexington where he also had a post-doctoral fellowship, served on the faculty of the Department of Pharmacology and had a rotating internship. His residency in psychiatry was at the Massachusetts General Hospital (1970-1972) and at the Dartmouth-Hitchcock Medical Center (1972-1973). He joined the Dartmouth faculty in Psychiatry in 1973 and in Pharmacology and Toxicology in 1976. His major clinical assignment has been at the VA Medical Center, White River Junction, where he served as staff psychiatrist (1973-1978), and Chief of Psychiatry (1978-1989). He has been Executive Director of the U. S. Department of Veterans Affairs National Center for Post-Traumatic Stress Disorder (PTSD) and Professor of Psychiatry and of Pharmacology and Toxicology at Dartmouth Medical School. He has worked with PTSD patients as a clinician and researcher for thirty-five years and has published extensively on stress and PTSD, biological psychiatry, psychopharmacology, and clinical outcome studies on depression, anxiety, schizophrenia, and chemical dependency. He has over 200 publications, including seventeen books and monographs. Listed in The Best Doctors in America, he is a Distinguished Lifetime Fellow of the American Psychiatric Association, past-president of the International Society for Traumatic Stress Studies (ISTSS), Chair of the scientific advisory board of the Anxiety Disorders Association of America and has served on many VA, DoD and NIMH research, education and policy committees. He has received many honors including the ISTSS Lifetime Achievement Award in 1999.
Re-Engineering Systems for Primary Care Treatment of PTSD ($1,242,100) 2007-2009. VA HSR&D. Schnurr PP & Friedman MJ, co-principal investigators
PTSD/TBI Clinical Consortium Study Site Award ($1,500,000) 2008-2013. DoD CDMRP. McAllister TW & Friedman MJ, co-principal investigators
Lecture medical students in SBM on PTSD
Teach seminars to psychiatry residents on the neurobiology and pharmacological treatment of PTSD.
Defining Treatment-Resistant Posttraumatic Stress Disorder: A Framework for Future Research.
Eradicating Traumatic Memories: Implications for PTSD Treatment.
VA's National PTSD Brain Bank: a National Resource for Research.
Mobile Mindfulness Intervention on an Acute Psychiatric Unit: Feasibility and Acceptability Study.
Pharmacological management of posttraumatic stress disorder.
Considering future pharmacotherapy for PTSD.
Changes to the Definition of Posttraumatic Stress Disorder in the DSM-5-Reply.
Seeking the Best Bereavement-Related Diagnostic Criteria.
How and why does the pharmaceutical management of PTSD differ between men and women?
Correcting Misconceptions About the Diagnostic Criteria for Posttraumatic Stress Disorder in DSM-5.